Viewing Study NCT06004661

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:18 PM
Ignite Modification Date: 2026-02-01 @ 11:05 PM
Study NCT ID: NCT06004661
Status: RECRUITING
Last Update Posted: 2025-11-25
First Post: 2023-06-29
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Castration-Resistant Prostate Cancer (mCRPC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer View
None Prostate-specific membrane antigen View
None PSMA View
None Metastatic Castration-Resistant Prostate Cancer View
None mCRPC View
None Renal impairment View
None Moderately impaired renal function View
None Severely impaired renal function View
None Normal renal function View
None lutetium (177Lu) vipivotide tetraxetan View
None AAA617 View
None Dosimetry View
None QTc prolongation View
None post marketing requirement View